drugset / Trial / NCT05855330

Arginine Replacement Therapy in COVID-19

NCT05855330

Phase 2 Recruiting 21 enrolled Emory University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed at the Children's Healthcare of Atlanta, Arthur M. Blank Hospital. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.

Timeline

Start
2024-01-08
Primary completion
2028-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator L-arginine Small molecule 25 mg/kg Intravenous
Comparator L-arginine Small molecule 100 mg/kg Intravenous

Indications